Adverse events associated with postoperative outcomes of adjuvant anti‐PD‐1 antibody therapy in both acral and non‐acral cutaneous melanomas: A multicenter, observational, post hoc analysis study

Abstract

AbstractSince anti‐PD‐1 Abs can cause irreversible immune‐related adverse events (irAEs), the associations between their efficacies and the incidence of irAEs are important to evaluate the use of anti‐PD‐1Abs for the treatment of melanoma, especially in the adjuvant setting. The purpose of this post hoc analysis study was to retrospectively analyze the associations between recurrence‐free survival (RFS) at 12 months and the onset of any irAEs in 31 non‐acral cutaneous and 30 acral melanoma cases treated with anti‐PD‐1 Abs therapy at the adjuvant setting in Asians. There were 20 cases with greater than grade 1 AEs in both the acral and non‐acral cutaneous groups. Of the acral melanoma, 10 cases were nails or toes, and 20 cases were soles and heels. The log‐rank test showed that RFS was better in cases with AEs than in cases without AEs. The present study suggested that the different profiles of irAEs between non‐acral cutaneous and acral melanoma might correlate with the different response to anti‐PD1 Abs of melanoma in the adjuvant setting.